Novartis Pharmaceuticals Corporation Reports Findings in Inflammatory Bowel Disease (Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials)

Press/Media

Period14 Mar 2024

Media coverage

1

Media coverage

  • TitleNovartis Pharmaceuticals Corporation Reports Findings in Inflammatory Bowel Disease (Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials)
    Media name/outletDaily Marketing News
    Country/TerritoryUnited States
    Date14/03/24
    PersonsMark Lebwohl